Shenying Fang1, Yuling Wang1, Dawen Sui1, Huey Liu1, Merrick I Ross1, Jeffrey E Gershenwald1, Janice N Cormier1, Richard E Royal1, Anthony Lucci1, Christopher W Schacherer1, Julie M Gardner1, John D Reveille1, Roland L Bassett1, Li-E Wang1, Qingyi Wei1, Christopher I Amos1, Jeffrey E Lee2. 1. Shenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH. 2. Shenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, Roland L. Bassett, Li-E Wang, and Jeffrey E. Lee, University of Texas MD Anderson Cancer Center; John D. Reveille, University of Texas Health Science Center at Houston, Houston, TX; Qingyi Wei, Duke University School of Medicine, Durham, NC; and Christopher I. Amos, Geisel College of Medicine, Dartmouth College, Lebanon, NH. jelee@mdanderson.org.
Abstract
PURPOSE: To investigate the association between blood levels of C-reactive protein (CRP) in patients with melanoma and overall survival (OS), melanoma-specific survival (MSS), and disease-free survival. PATIENTS AND METHODS: Two independent sets of plasma samples from a total of 1,144 patients with melanoma (587 initial and 557 confirmatory) were available for CRP determination. Kaplan-Meier method and Cox regression were used to evaluate the relationship between CRP and clinical outcome. Among 115 patients who underwent sequential blood draws, we evaluated the relationship between change in disease status and change in CRP using nonparametric tests. RESULTS: Elevated CRP level was associated with poorer OS and MSS in the initial, confirmatory, and combined data sets (combined data set: OS hazard ratio, 1.44 per unit increase of logarithmic CRP; 95% CI, 1.30 to 1.59; P < .001; MSS hazard ratio, 1.51 per unit increase of logarithmic CRP; 95% CI, 1.36 to 1.68; P < .001). These findings persisted after multivariable adjustment. As compared with CRP < 10 mg/L, CRP ≥ 10 mg/L conferred poorer OS in patients with any-stage, stage I/II, or stage III/IV disease and poorer disease-free survival in those with stage I/II disease. In patients who underwent sequential evaluation of CRP, an association was identified between an increase in CRP and melanoma disease progression. CONCLUSION: CRP is an independent prognostic marker in patients with melanoma. CRP measurement should be considered for incorporation into prospective studies of outcome in patients with melanoma and clinical trials of systemic therapies for those with melanoma.
PURPOSE: To investigate the association between blood levels of C-reactive protein (CRP) in patients with melanoma and overall survival (OS), melanoma-specific survival (MSS), and disease-free survival. PATIENTS AND METHODS: Two independent sets of plasma samples from a total of 1,144 patients with melanoma (587 initial and 557 confirmatory) were available for CRP determination. Kaplan-Meier method and Cox regression were used to evaluate the relationship between CRP and clinical outcome. Among 115 patients who underwent sequential blood draws, we evaluated the relationship between change in disease status and change in CRP using nonparametric tests. RESULTS: Elevated CRP level was associated with poorer OS and MSS in the initial, confirmatory, and combined data sets (combined data set: OS hazard ratio, 1.44 per unit increase of logarithmic CRP; 95% CI, 1.30 to 1.59; P < .001; MSS hazard ratio, 1.51 per unit increase of logarithmic CRP; 95% CI, 1.36 to 1.68; P < .001). These findings persisted after multivariable adjustment. As compared with CRP < 10 mg/L, CRP ≥ 10 mg/L conferred poorer OS in patients with any-stage, stage I/II, or stage III/IV disease and poorer disease-free survival in those with stage I/II disease. In patients who underwent sequential evaluation of CRP, an association was identified between an increase in CRP and melanoma disease progression. CONCLUSION:CRP is an independent prognostic marker in patients with melanoma. CRP measurement should be considered for incorporation into prospective studies of outcome in patients with melanoma and clinical trials of systemic therapies for those with melanoma.
Authors: Christopher I Amos; Li-E Wang; Jeffrey E Lee; Jeffrey E Gershenwald; Wei V Chen; Shenying Fang; Roman Kosoy; Mingfeng Zhang; Abrar A Qureshi; Selina Vattathil; Christopher W Schacherer; Julie M Gardner; Yuling Wang; D Tim Bishop; Jennifer H Barrett; Stuart MacGregor; Nicholas K Hayward; Nicholas G Martin; David L Duffy; Graham J Mann; Anne Cust; John Hopper; Kevin M Brown; Elizabeth A Grimm; Yaji Xu; Younghun Han; Kaiyan Jing; Caitlin McHugh; Cathy C Laurie; Kim F Doheny; Elizabeth W Pugh; Michael F Seldin; Jiali Han; Qingyi Wei Journal: Hum Mol Genet Date: 2011-09-17 Impact factor: 6.150
Authors: Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245
Authors: T T Pelliniemi; K Irjala; K Mattila; K Pulkki; A Rajamäki; A Tienhaara; M Laakso; R Lahtinen Journal: Blood Date: 1995-02-01 Impact factor: 22.113
Authors: Andre Pascal Kengne; G David Batty; Mark Hamer; Emmanuel Stamatakis; Sébastien Czernichow Journal: Diabetes Care Date: 2011-12-30 Impact factor: 19.112
Authors: Jennifer L McQuade; Carrie R Daniel; Kenneth R Hess; Carmen Mak; Daniel Y Wang; Rajat R Rai; John J Park; Lauren E Haydu; Christine Spencer; Matthew Wongchenko; Stephen Lane; Dung-Yang Lee; Mathilde Kaper; Meredith McKean; Kathryn E Beckermann; Samuel M Rubinstein; Isabelle Rooney; Luna Musib; Nageshwar Budha; Jessie Hsu; Theodore S Nowicki; Alexandre Avila; Tomas Haas; Maneka Puligandla; Sandra Lee; Shenying Fang; Jennifer A Wargo; Jeffrey E Gershenwald; Jeffrey E Lee; Patrick Hwu; Paul B Chapman; Jeffrey A Sosman; Dirk Schadendorf; Jean-Jacques Grob; Keith T Flaherty; Dana Walker; Yibing Yan; Edward McKenna; Jeffrey J Legos; Matteo S Carlino; Antoni Ribas; John M Kirkwood; Georgina V Long; Douglas B Johnson; Alexander M Menzies; Michael A Davies Journal: Lancet Oncol Date: 2018-02-12 Impact factor: 41.316
Authors: Shenying Fang; Dawen Sui; Yuling Wang; Huey Liu; Yi-Ju Chiang; Merrick I Ross; Jeffrey E Gershenwald; Janice N Cormier; Richard E Royal; Anthony Lucci; Jennifer Wargo; Mimi I Hu; Julie M Gardner; John D Reveille; Roland L Bassett; Qingyi Wei; Christopher I Amos; Jeffrey E Lee Journal: J Clin Oncol Date: 2016-03-21 Impact factor: 44.544
Authors: Yuling Wang; Vijaya Ramachandran; Dawen Sui; Kejing Xu; Lauren E Haydu; Shenying Fang; Jennifer L McQuade; Sarah B Fisher; Anthony Lucci; Emily Z Keung; Jennifer Wargo; Jeffrey E Gershenwald; Merrick I Ross; Jeffrey E Lee Journal: J Invest Dermatol Date: 2021-12-21 Impact factor: 7.590